“We are planning to launch 25 products in the US generics segment in FY25,” said Pranav Amin, MD of Alembic Pharma, in an interview to ET. “We have EIRs (establishment inspection reports) for all of our facilities, so there is no regulatory overhang,” Amin added. US business accounts for 28% of Alembic Pharma’s revenue of ₹6,229 crore, which grew 19% year-on-year (YoY) in FY24. The India business that accounts for 35% grew 7% in FY24.
Amin said Alembic is targeting R&D spending of ₹550-₹600 crore in FY25, primarily for developing a pipeline of products for the US market, largely consisting of complex formulations such as injectables, ophthalmic, oncology, inhalation, and dermatology products. Amin added that the expenditure on capex will be low for next two years and will be limited to debottlenecking of the existing facilities.
The Vadodara-based drug maker, which has been around for over a century, is a late entrant in the US market. It has more than made up for it. It has been on an investment overdrive, spending about ₹700-₹750 crore per annum on R&D to build a complex pipeline of products for the US market, and spent more than ₹1,800 crore to build three new USFDA-compliant facilities to manufacture these products. The India business of Alembic Pharma has seen growth moderation due to lower offtake of antibiotics. “I expect all the businesses including India to grow by 10% or so,” Amin said.
“Every year we will launch 20-25 new products including line extensions. We will continue to do so as 2.5%-3% growth in India business is driven by new launches,” said RK Baheti, director, finance.
